Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia.
Disseminated aspergillosis in immunocompromised patients has a mortality rate of almost 100%. Despite the development of new antifungal agents, the outcome of disseminated aspergillosis has only improved slightly, particular in patients with central nervous system (CNS) involvement. The use of combination antifungal therapy might improve the dismal outcome of disseminated aspergillosis. We describe a critically ill adolescent with acute lymphoblastic leukemia who was successfully treated with voriconazole and caspofungin for disseminated aspergillosis with involvement of the lung, brain and thyroid gland.
Zwitserloot
Annelies M
AM
Department of Pediatric Hematology and Oncology, Radboud University Nijmegen Medical Centre, The Netherlands.
Warris
Adilia
A
van't Hek
Louis G
LG
van Die
Lya E
LE
Verweij
Paul E
PE
Mavinkurve-Groothuis
Annelies M C
AM
D000293:Adolescent; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001232:Aspergillus fumigatus; D000077336:Caspofungin; D020314:Central Nervous System Fungal Infections; D054714:Echinocandins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D055666:Lipopeptides; D008172:Lung Diseases, Fungal; D009894:Opportunistic Infections; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000382:microbiology; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D065819:Voriconazole